1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Natural Killer Cell Lymphomas – Pipeline Review, H1 2013

Natural Killer Cell Lymphomas – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 39 pages

Natural Killer Cell Lymphomas – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Natural Killer Cell Lymphomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Natural Killer Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Natural Killer Cell Lymphomas. Natural Killer Cell Lymphomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Natural Killer Cell Lymphomas.
- A review of the Natural Killer Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Natural Killer Cell Lymphomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Natural Killer Cell Lymphomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Natural Killer Cell Lymphomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Natural Killer Cell Lymphomas - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Natural Killer Cell Lymphomas Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Natural Killer Cell Lymphomas 7
Natural Killer Cell Lymphomas Therapeutics under Development by Companies 9
Natural Killer Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Natural Killer Cell Lymphomas Therapeutics - Products under Development by Companies 14
Natural Killer Cell Lymphomas Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Natural Killer Cell Lymphomas Therapeutics Development 16
Kyowa Hakko Kirin Co., Ltd. 16
Seattle Genetics, Inc. 17
Natural Killer Cell Lymphomas - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
mogamulizumab - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Dexamethasone + Ifosfamide + Cisplatin + Etoposide - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Umbilical Cord Blood Transplantation - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
brentuximab vedotin + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vicristine sulfate] - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 30
brentuximab vedotin + [cyclophosphamide] + [doxorubicin] + [prednisone] - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 32
131I-BC8 (Anti-CD45) Antibody + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Natural Killer Cell Lymphomas Therapeutics - Drug Profile Updates 34
Natural Killer Cell Lymphomas Therapeutics - Discontinued Products 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39



List of Tables

Number of Products Under Development for Natural Killer Cell Lymphomas, H1 2013 7
Products under Development for Natural Killer Cell Lymphomas - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Kyowa Hakko Kirin Co., Ltd., H1 2013 16
Seattle Genetics, Inc., H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Natural Killer Cell Lymphomas Therapeutics - Drug Profile Updates 34
Natural Killer Cell Lymphomas Therapeutics - Discontinued Products 37



List of Figures

Number of Products under Development for Natural Killer Cell Lymphomas, H1 2013 7
Products under Development for Natural Killer Cell Lymphomas - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19 Summary Cancer vaccines are being ...

Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts

Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts

  • $ 2995
  • Industry report
  • September 2016
  • by Currentpartnering

The Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the regenerative medicine including ...

Bronchiolitis Obliterans Global Clinical Trials Review, H2, 2016

Bronchiolitis Obliterans Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Bronchiolitis Obliterans Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Bronchiolitis Obliterans Global Clinical Trials Review, H2, 2016" provides an overview of ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Belgium and the UK

  • November 2016
    4 pages
  • Oncology  

  • Belgium  

    United Kingdom  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    12 pages
  • Therapy  

  • United States  

    Brazil  

View report >

Therapy Market in the US - Forecast

  • November 2016
    48 pages
  • Therapy  

  • United States  

View report >

Related Market Segments :

Cell Therapy
Lymphoma

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.